Ollech Ayelet, Yousif Rame, Kruse Lacey, Wagner Annette, Kenner-Bell Brandi, Chamlin Sarah, Yun Duri, Shen Lisa, Vivar Karina, Reynolds Megan, Paller Amy S, Mancini Anthony J
Division of Dermatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.
Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
J Am Acad Dermatol. 2020 Jun;82(6):1409-1414. doi: 10.1016/j.jaad.2020.01.064. Epub 2020 Feb 4.
Data regarding the treatment of periorificial dermatitis with topical calcineurin inhibitors (TCI) in the pediatric population are limited.
To assess the clinical utility of TCI in pediatric patients with periorificial dermatitis.
A retrospective medical record review of all pediatric patients with periorificial dermatitis treated with TCIs was performed. Follow-up via telephone was performed to capture missing data.
A total of 132 patients met the inclusion criteria. The median age at diagnosis was 4.2 years (interquartile range, 2.3-8.2). The median follow-up was 5.2 months (interquartile range, 2.1-11.7). Seventy-two patients had evaluable follow-up data. Of these, 48 (67%) patients were treated with TCI alone, 12 (16.7%) were treated with a combination of TCI and topical metronidazole, and 9 (12.5%) were treated with a combination of TCI and a systemic antibiotic. Complete response was noted in 68.8% of patients treated with TCI alone, in 75% of patients treated with TCI and metronidazole, and in 77.8% of patients treated with TCI and a systemic antibiotic. Adverse events were rare and mild in severity.
Topical calcineurin inhibitors are an effective therapeutic option for pediatric patients with periorificial dermatitis and were well tolerated in this cohort.
关于儿童人群中使用局部钙调神经磷酸酶抑制剂（TCI）治疗口周皮炎的数据有限。
评估TCI在儿童口周皮炎患者中的临床应用价值。
对所有接受TCI治疗的儿童口周皮炎患者进行回顾性病历审查。通过电话随访以获取缺失数据。
共有132例患者符合纳入标准。诊断时的中位年龄为4.2岁（四分位间距，2.3 - 8.2）。中位随访时间为5.2个月（四分位间距，2.1 - 11.7）。72例患者有可评估的随访数据。其中，48例（67%）患者仅接受TCI治疗，12例（16.7%）患者接受TCI与局部甲硝唑联合治疗，9例（12.5%）患者接受TCI与全身用抗生素联合治疗。仅接受TCI治疗的患者中68.8%有完全缓解，接受TCI与甲硝唑联合治疗的患者中75%有完全缓解，接受TCI与全身用抗生素联合治疗的患者中77.8%有完全缓解。不良事件罕见且严重程度较轻。
局部钙调神经磷酸酶抑制剂是儿童口周皮炎患者的一种有效治疗选择，且在该队列中耐受性良好。
